Mechanism-based pharmacological management of chemotherapy-induced neuropathic pain from preclinical studies to clinical prospective: platinum-based drugs …

N Zafari, M Velayati, M Maftooh… - Current …, 2023 - ingentaconnect.com
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a painful condition,
experienced by patients undergoing chemotherapy with some specific drugs, such as …

Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain

M Sisignano, R Baron, K Scholich… - Nature Reviews …, 2014 - nature.com
Chemotherapy-induced peripheral neuropathic pain (CIPNP)—a severe adverse effect
observed in up to 80% of patients during treatment with antineoplastic drugs—limits the …

Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

K Sałat - Pharmacological reports, 2020 - Springer
Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …

[HTML][HTML] Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues

EH Bae, MK Greenwald, AG Schwartz - Neurotherapeutics, 2021 - Elsevier
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious and often persistent
adverse consequence of certain chemotherapeutic agents. It is a major dose-limiting factor …

Evidence-based treatment of pain in chemotherapy-induced peripheral neuropathy

RS D'Souza, GAM Alvarez… - Current Pain and …, 2023 - Springer
Abstract Purpose of Review Chemotherapy-induced peripheral neuropathy (CIPN) is a
debilitating and often painful condition that occurs after administration of chemotherapeutic …

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

K Sałat - Pharmacological Reports, 2020 - Springer
Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy

M Bakogeorgos, V Georgoulias - Expert review of anticancer …, 2017 - Taylor & Francis
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN), a common adverse
effect of several chemotherapeutic agents, has a significant impact on quality of life and may …

An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy‐induced peripheral neuropathy, based on …

H Bouchenaki, A Danigo, F Sturtz, R Hajj… - Fundamental & …, 2021 - Wiley Online Library
Chemotherapy‐induced peripheral neuropathy (CIPN) is a major dose‐limiting side effect
induced by a variety of chemotherapeutic agents. Symptoms are mainly sensory: pain …

Mechanisms involved in the development of chemotherapy-induced neuropathy

JA Boyette-Davis, ET Walters, PM Dougherty - Pain management, 2015 - Taylor & Francis
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition
seen in patients undergoing treatment with common agents such as vincristine, paclitaxel …

Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy

Y Li, MB Lustberg, S Hu - Cancers, 2021 - mdpi.com
Simple Summary Chemotherapy-induced peripheral neuropathy (CIPN) is a common and
persistent complication of commonly used chemotherapy drugs. This article provides an …